Latest Content

As AI proliferates, patients, caregivers, and others outside the medical world are using its tools to deal with cancer, but not always in obvious ways.

Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.

Phase 3 trials found oveporexton improved wakefulness, sleepiness, and cataplexy in narcolepsy type 1, with insomnia and urinary frequency common.

The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.

A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.

A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.

Panelists say drug price negotiation, Medicaid changes, prior authorization, and 340B reform strain community oncology.

Symptom-tracking tools may improve awareness and patient-clinician communication but can also add stress.

Payers cover novel cancer drugs but not the staffing, training, and monitoring to deliver them, leaving practices to absorb costs.